Cipla to introduce Afrezza, an inhaled insulin for diabetes, offering convenience but not advised for lung-related concerns.

The FDA approved its short-acting insulin, Fiasp (insulin aspart injection) in September, and its long-acting insulin Tresiba (insulin degludec) got US approval late last year. [caption id ...

Summary: Insulin detemir is a long-acting, neutral, and soluble insulin analogue with a lower within-subject variability of fasting plasma glucose levels than isophane insulin human (NPH insulin ...

Several years ago, NSYNC’s Lance bass noticed he felt run down. Doctors diagnosed him with type 2 diabetes but drugs didn't ...

According to a comprehensive report by Future Market Insights (FMI), the global pediatric diabetes therapeutic market is set to experience substantial growth, with estimates projecting a rise from USD ...

The global rapid acting insulin market was valued at $7,100 million in 2019, and is projected to reach $8,925 million by 2027 at a CAGR of 4.1% from 2020 to 2027. The growth of the global rapid acting ...

In 29% of patients, home oral glucose lowering agents were held during hospitalization and scheduled insulin was not initiated. Although the reasons for holding home medications were not collected, ...

(NASDAQ:MODD) ("Modular Medical"), an insulin delivery technology company ... of MODD1 pump as a delivery system for FDA-approved, short acting peptides, as a personalized alternative for people ...

The quickest way to lower your blood sugar is to take fast-acting insulin. However ... some exercises — particularly short bursts of strenuous activity — can briefly increase blood sugar ...